BridgeBio Entered into a Collaboration with Helsinn to Co-Develop and Co-Commercialize GPX4 Program for Multiple Cancer
Shots:
- The collaboration builds on the March 2021 license agreement for $2.45B to develop BridgeBio’s infigratinib (FGFR inhibitor) in oncology indications
- Under the non-exclusive agreement, BridgeBio is eligible to receive a profit share on US sales along with royalties on Ex-US sales. The companies get the option to collaborate on preclinical oncology programs & will share global development responsibilities for each program
- The agreement will utilize BridgeBio’s drug discovery expertise and Helsinn’s clinical development and commercial capabilities to develop & commercialize the GPX4 program for cancer. Helsinn to get exclusive manufacturing and commercial rights to the programs
| Ref: BridgeBio | Image: LinkedIn
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com